Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy
Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald · 2026
Read Extracellularly Activatable Conjugates of RGD Peptidomimetics and Cryptophycin for αVβ3‐Targeted Cancer Therapy by Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13628569.txt.
Description
Dominic Seißenschmidt and three colleagues designed small drug conjugates that carry a highly potent toxin to tumours displaying a marker called integrin alpha-v beta-3, published in 2026. Each conjugate joins a targeting piece modelled on the RGD peptide pattern to cryptophycin, a cell-killing compound too toxic to use on its own.
The connector between the parts is built to be cut by neutrophil elastase, an enzyme active around tumours, so the payload releases outside the target cells. The conjugates stayed stable in human plasma, kept their grip on the integrin, and once cut loose, the freed toxin killed cancer cells at extremely low concentrations. Carefully built control versions confirmed that both targeting and the correct linker geometry are essential.
Catalog record
| CREATOR | Dominic Seißenschmidt, Henriette Hartung, Jonah Kammer, Norbert Sewald |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24013 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |